BEYOND THE GATES/FAUCI ERA

What happens next?

BLOCKBUSTER DRUGS BECOME RIP-OFFS

The unsustainability of the Gates/Fauci Big Pharma model of drug development is now plain for all to see.

It started to sound a bit dodgy when ‘Glybera’, the first gene therapy drug to be launched in Europe, was priced at $1M, and unsurprisingly, was withdrawn from the market having sold diddly-squat, see Goodbye Glybera! The World’s First Gene Therapy will be Withdrawn.

Then, Gilead Sciences Inc.’s drug ‘Yescarta’ had only been administered to five patients two months after launch in the US. The price tag for the treatment was $373,000. The waiting list amounted to over 200, but patients’ insurance would not cover the cost.

Just after reading about Yescarta, I read of Spark Therapeutics Inc.’s drug ‘Luxturna’ priced at $850,000 per treatment being judged vastly overpriced in the US by the Institute for Clinical and Economic Review.

Novartis launched ‘Kymriah’ in the US in August, 2017 with a $475,000 price tag.

In, 2019, media reports announced the launch…